NCT02526316View on ClinicalTrials.gov

Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
HPV-induced Cancers
Interventions
BIOLOGICAL

P16_37-63 peptide combined with Montanide® ISA-51 VG

Patients will receive P16\_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period

BIOLOGICAL

P16_37-63 peptide without Montanide® ISA-51 VG

Patients will receive 30 mcg P16\_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.

Trial Locations (1)

60488

Krankenhaus Nordwest, Frankfurt

All Listed Sponsors
lead

Oryx GmbH & Co. KG

INDUSTRY

NCT02526316 - Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers | Biotech Hunter | Biotech Hunter